Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.

Pardanani A, Tefferi A.

Leuk Res. 2004 May;28 Suppl 1:S47-52. Review.

PMID:
15036941
2.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A.

Blood. 2003 Nov 1;102(9):3093-6. Epub 2003 Jul 3.

3.

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE.

Blood. 2004 Apr 15;103(8):2879-91. Epub 2003 Nov 20. Review.

4.

[Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].

Menif S, Ben Romdhane N, Hafsia R.

Rev Med Interne. 2008 Jan;29(1):65-7. Epub 2007 Oct 25. French.

PMID:
18036706
5.

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.

Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A.

Blood. 2004 Nov 15;104(10):3038-45. Epub 2004 Jul 29.

6.

[Disorders with eosinophilia, treatment of hypereosinophilic syndrome].

Borbényi Z.

Orv Hetil. 2005 May 1;146(18 Suppl 1):911-6. Review. Hungarian.

PMID:
15921304
7.

The results of imatinib therapy for patients with primary eosinophilic disorders.

Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J, Reiter A, Hochhaus A, Holowiecki J.

Eur J Haematol. 2006 Jun;76(6):535-6. Epub 2006 Apr 11. No abstract available.

PMID:
16608506
8.

The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C.

Haematologica. 2005 May;90(5):596-601.

9.

Imatinib-responsive hypereosinophilic syndrome.

Robyn J.

Leuk Res. 2006 Aug;30(8):915-6. Epub 2006 Mar 13. No abstract available.

PMID:
16530830
10.

Response to imatinib mesylate in patients with hypereosinophilic syndrome.

Arefi M, García JL, Briz MM, de Arriba F, Rodríguez JN, Martín-Núñez G, Martínez J, López J, Suárez JG, Moreno MJ, Merino MA, Gutiérrez NC, Hernández-Rivas JM.

Int J Hematol. 2012 Sep;96(3):320-6. doi: 10.1007/s12185-012-1141-7. Epub 2012 Jul 18.

PMID:
22806436
11.

FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.

Wang LN, Pan Q, Fu JF, Shi JY, Jin J, Li JM, Hu J, Zhao WL, Chen Z, Chen SJ.

Chin Med J (Engl). 2008 May 20;121(10):867-73.

PMID:
18706197
12.

[FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].

Nemchenko IS, Khoroshko ND, Turkina AG, Sokolova MA, Kokhno AV, Semenova EA, Zakharova AV.

Ter Arkh. 2005;77(7):90-2. Russian. No abstract available.

PMID:
16116920
13.

A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.

Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, Simon HU.

Allergy. 2009 Jun;64(6):913-8. doi: 10.1111/j.1398-9995.2009.01943.x. Epub 2009 Feb 7.

PMID:
19210352
14.

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.

Helbig G, Kyrcz-Krzemień S.

Am J Hematol. 2014 Jan;89(1):115. doi: 10.1002/ajh.23588. Epub 2013 Oct 15. No abstract available.

15.

[The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].

Li B, Zhang GS, Dai CW, Pei MF.

Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):448-52. Chinese.

PMID:
15854548
16.

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.

Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J.

Br J Haematol. 2008 Apr;141(2):200-4. doi: 10.1111/j.1365-2141.2008.07033.x. Epub 2008 Feb 26.

PMID:
18307562
17.
18.

Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.

Pitini V, Sturniolo G, Cavallari V, Arrigo C.

Br J Haematol. 2006 Jan;132(2):123. No abstract available.

PMID:
16398645
19.

The hypereosinophilic syndromes: current concepts and treatments.

Gleich GJ, Leiferman KM.

Br J Haematol. 2009 May;145(3):271-85. doi: 10.1111/j.1365-2141.2009.07599.x. Review.

PMID:
19243381
20.

Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.

Coutré S, Gotlib J.

Semin Cancer Biol. 2004 Feb;14(1):23-31. Review. Erratum in: Semin Cancer Biol. 2004 Aug;14(4):306. Corrected and republished in: Semin Cancer Biol. 2004 Aug;14(4):307-15.

PMID:
14757533

Supplemental Content

Support Center